Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr

Quick Summary:

In the coming quarters, the company plans to grow its US business too.

The company took some write-offs on impaired assets in previous years, which had brought down the taxation, clarified R K Baheti, group CFO, Alembic.

We have started working on that, and expect that the API business will be back on the growth path in FY26,” Baheti said.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaAustraliaCanada

Topics: Alembic Pharma Net profit RK Baheti Q4FY25 results API business Shaunak Amin India branded business Revenue growth US generics

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-05-06 @ 16:41:51 (10 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 354 words

Reading Time: 2 minutes read

Sentences: 16 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 28437393

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 310 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions